Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Start-Up Spotlight: Actinium Pharmaceuticals, Inc.

Posted on June 9th, 2017 by in Pharma R&D


Actinium logo

Exciting developments are taking place at Actinium Pharmaceuticals, Inc. in New York City. Dr. David Gould, SVP Corporate Development, discusses the biopharma’s important research, which has resulted in a product that helps patients in need of bone marrow transplants.

What does Actinium do?

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The company’s lead product candidate, Iomab-B, is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

Tell us more about your lead product and your progress with it.

Iomab-B was developed at the Fred Hutchinson Cancer Research Center, where it has been studied in almost 300 patients in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). In a Phase 2 clinical study in 68 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced complete remissions in 100% of patients and patients experienced transplant engraftment at day 28.

Why is Actinium’s work valuable? What impact will it have on the industry?

Actinium believes that Iomab-B, if approved, will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates.

Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors.

Why is this important now?

Bone marrow transplantation is one of the fastest-growing hospital procedures, especially in older patients; however, more can be done to expand the number of patients eligible for transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers, but the current standard preparation for a transplant requires intensive chemotherapy and/or total body irradiation that results in significant toxicities.

What will be the next steps for the company?

Iomab-B is currently being studied in a 150-patient, multicenter pivotal Phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. Actinium’s second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial.

What Actinium’s Leaders Have to Say:

“Iomab-B has the potential to revolutionize the way we transplant patients with acute leukemia, particularly amongst the most difficult-to-treat older patients with relapsed or refractory acute leukemia”.

– Dr. Mark Berger, Chief Medical Officer

Are you currently looking for partners or investment?

We are interested in meeting with potential corporate partners or institutional investors that may have an interest in our programs.

Contact David Gould, or follow Actinium Pharma:

Read about more leading-edge biotech and pharmaceutical start-ups with The Hive.


All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales